Abiopharma

Badawi Paul 🔴 sold 37.2K shares of Sight Sciences, Inc. (SGHT) at $7.48 Transaction Date: Jan 02, 2026 | Filing ID: 005006

HAYDEN JEREMY B. 🔴 sold 11.2K shares of Sight Sciences, Inc. (SGHT) at $7.82 Transaction Date: Jan 05, 2026 | Filing ID: 004999

Badawi David 🔴 sold 9.7K shares of Sight Sciences, Inc. (SGHT) at $7.82 Transaction Date: Jan 02, 2026 | Filing ID: 004994

Rodberg James 🔴 sold 5.0K shares of Sight Sciences, Inc. (SGHT) at $7.82 Transaction Date: Jan 05, 2026 | Filing ID: 004987

Bauerlein Alison 🔴 sold 20.5K shares of Sight Sciences, Inc. (SGHT) at $7.82 Transaction Date: Jan 05, 2026 | Filing ID: 004979

Taylor Brenton 🔴 sold 619 shares of Sight Sciences, Inc. (SGHT) at $7.48 Transaction Date: Jan 06, 2026 | Filing ID: 004972

Miles Patrick 🔴 sold 100.0K shares of Alphatec Holdings, Inc. (ATEC) at $21.01 ($2.1M) Transaction Date: Jan 05, 2026 | Filing ID: 000002

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Director Lang James Paul 🟢 acquired 2.2K shares (1 derivative) of HALOZYME THERAPEUTICS, INC. (HALO) at $70.31 Transaction Date: Jan 02, 2026 | Filing ID: 000007

Director Connaughton Bernadette 🔴 sold 2.0K shares of HALOZYME THERAPEUTICS, INC. (HALO) at $70.25 Transaction Date: Jan 05, 2026 | Filing ID: 000006

Snyder Mark Howard 🟡 adjusted position in 4.2K shares (1 derivative) of HALOZYME THERAPEUTICS, INC. (HALO) at $70.31 Transaction Date: Jan 03, 2026 | Filing ID: 000005

Director Booth Robert F. 🟢 acquired 42.2K shares (2 derivative) of Summit Therapeutics Inc. (SMMT) at $17.52 Transaction Date: Jan 02, 2026 | Filing ID: 000003

Director Xia Yu 🟢 acquired 35.0K shares (1 derivative) of Summit Therapeutics Inc. (SMMT) at $17.52 Transaction Date: Jan 02, 2026 | Filing ID: 000002

Ganot Ilan 🟡 adjusted position in 1.1K shares (1 derivative) of Solid Biosciences Inc. (SLDB) at $5.43 Transaction Date: Jan 03, 2026 | Filing ID: 004953

Director Huber Jeff 🟢 acquired 44.9K shares (2 derivative) of Summit Therapeutics Inc. (SMMT) at $17.52 Transaction Date: Jan 02, 2026 | Filing ID: 000003